Study to Evaluate Safety, Tolerability and Efficacy of Saroglitazar Mg in Patients With Primary Biliary Cholangitis

Phase 2

Completed

• Conditions: Primary Biliary Cirrhosis
• Interventions: Drug: Saroglitazar magnesium 2 mg; Drug: Saroglitazar magnesium 4 mg; Drug: Placebo Oral Tablet

• Registration Number: NCT03112681
• Lead Sponsor: Zydus Therapeutics Inc.

Brief Summary

prospective, multicenter, randomized, double-blind, placebo-controlled study to evaluate safety, tolerability and efficacy of saroglitazar magnesium 2 mg, 4 mg in Patients with Primary Biliary Cholangitis. A total 36 subjects will be enrolled in a ratio of 1:1:1 to receive either saroglitazar magnesium 2 mg or saroglitazar magnesium 4 mg or placebo.

Detailed Description

Study SARO.16.004.02 is a prospective, multicenter, randomized, double-blind, placebo-controlled study to evaluate safety, tolerability and efficacy of saroglitazar magnesium 2 mg, 4 mg in Patients with Primary Biliary Cholangitis.

A total 36 subjects will be enrolled in a ratio of 1:1:1 to receive either saroglitazar magnesium 2 mg or saroglitazar magnesium 4 mg or placebo. The primary objective is to investigate the effect of a 16-week treatment regimen of Saroglitazar magnesium 2 mg and 4 mg on ALP levels in patients with Primary Biliary Cholangitis.

Study Timeline

• Study First Submitted: 2017-04-10
• Study First Submitted QC: 2017-04-12
• Study First Posted: 2017-04-13
• Study Start: 2017-08-18
• Primary Completion: 2020-08-07
• Study Completion: 2020-08-07
• Status Verified: 2023-12
• Last Update Submitted: 2023-12-30
• Last Update Posted: 2024-01-05

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 37

Inclusion Criteria

1. Males or females, between 18 and 75 years of age, inclusive.

2. a) Patients on therapeutic doses of Ursodeoxycholic acid (UDCA) for ≥12 months and stable therapy for ≥3 months prior to enrolment.

   OR b) Patients who are unable to tolerate UDCA, and did not receive UDCA for at least 3 months from the date of screening.

3. History of confirmed Primary Biliary Cholangitis Diagnosis, based on American Association for the Study of Liver Disease [AASLD] and European Association for Study of the Liver [EASL] Practice Guidelines; [Lindor 2009; EASL 2009], as demonstrated by the presence of at least≥2 of the following 3 diagnostic factors:

   • History of elevated Alkaline Phosphatase levels for at least 6 months prior to Screening Visit 1
   • Positive antimitochondrial antibodies (AMA) titer or if AMA negative or in low titer (<1:80) PBC specific antibodies (anti-GP210 and/or anti-SP100 and/or antibodies against the major M2 components [PDC-E2, 2-oxo-glutaric acid dehydrogenase complex])
   • Liver biopsy consistent with PBC.

4. ALP ≥1.67x upper limit of normal (ULN) at Visit 1 and Visit 2 and with < 30% variance between the levels from Visit 1 to Visit 2.

5. Contraception: Female patients must be postmenopausal, surgically sterile, or if premenopausal, agree to use ≥ 1 effective method of contraception during the trial. Effective methods of contraception are considered to be Hormonal (e.g., contraceptive pill, patch, intramuscular implant or injection); or Double barrier method, i.e., (a) condom (male or female) or (b) diaphragm, with spermicide; or Intrauterine device (IUD); or Vasectomy (partner).

6. Must provide written informed consent and agree to comply with the trial protocol.

Exclusion Criteria

1. Consumption of >3 units of alcohol per day (>21 units per week) if male and >2 units of alcohol per day (>14 units per week) if female for at least 3 consecutive months in the last 5 years (Note: 1 unit = 12 ounces of beer, 4 ounces of wine or 1 ounce of spirits/hard liquor).

2. History or presence of other concomitant liver diseases including:

   • Hepatitis B or C virus (HCV, HBV) infection
   • Primary sclerosing cholangitis (PSC)
   • Alcoholic liver disease
   • Definite autoimmune liver disease or overlap syndrome
   • Non-alcoholic steatohepatitis (NASH)

3. Cirrhosis with complications, including history or presence of: spontaneous bacterial peritonitis, hepatocellular carcinoma, bilirubin > 2x ULN, ascites, encephalopathy, known esophageal varices or history of variceal bleeding and active or history of hepatorenal syndrome.

4. History of any venous thromboembolism, TIA, intracranial hemorrhage, neoplasm, arteriovenous malformation, vasculitis, bleeding disorder, coagulation disorders or screening blood tests that indicate altered coagulability (e.g. platelet count, aPTT, PTT or TT tests).

5. Patients with INR > ULN at visit 1.

6. Patients with total bilirubin > ULN at visit 1 that is not due to Gilbert's syndrome

7. Patients with >30% increase in ALT, total bilirubin, or INR between Visit 1 to Visit 2.

8. Patients with serum creatinine >ULN according to the gender at Visit 1.

9. Patients with abnormal total creatine kinase (CK) OR lipase OR amylase at Visit 1.

10. Unstable cardiovascular disease, including:

    • unstable angina, (i.e., new or worsening symptoms of coronary heart disease within the past 3 months), acute coronary syndrome within the past 6 months, acute myocardial infarction in the past 3 months or heart failure of New York Heart Association class (III - IV) or worsening congestive heart failure, or coronary artery intervention, within the past 6 months
    • history of (within prior 3 months) or current unstable cardiac dysrhythmias
    • uncontrolled hypertension (systolic blood pressure [BP] >160 mmHg and/or diastolic BP >100 mmHg)
    • stroke or transient ischemic attack within the prior 6 months

11. History of malignancy in the past 5 years and/or active neoplasm with the exception of resolved superficial nonmelanoma skin cancer.

12. Contraindications to Saroglitazar magnesium or has any conditions affecting the ability to evaluate the effects of Saroglitazar magnesium.

13. Known allergy, sensitivity or intolerance to the study drug, comparator or formulation ingredients.

14. Participation in any other clinical study within the previous 3 months of screening.

15. Illicit substance abuse within the past 6 months.

16. History or other evidence of severe illness or any other conditions that would make the patient, in the opinion of the investigator, unsuitable for the study (such as poorly controlled psychiatric disease, human immunodeficiency virus (HIV), coronary artery disease or active gastrointestinal conditions that might interfere with drug absorption).

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Saroglitazar magnesium 2 mg	Saroglitazar magnesium 2 mg	Saroglitazar magnesium 2 mg tablet Once daily for 16 weeks
Saroglitazar magnesium 4 mg	Saroglitazar magnesium 4 mg	Saroglitazar magnesium 4 mg tablet Once daily for 16 weeks
Placebo	Placebo Oral Tablet	Placebo tablet Once daily for 16 weeks

Primary Outcome Measures

Name	Time	Method
Effect of a 16-week Treatment Regimen of Saroglitazar Magnesium 2 mg and 4 mg on Alkaline Phosphatase (ALP) Levels in Patients With Primary Biliary Cholangitis.	Baseline and Week 16	Change in ALP levels after 16 weeks of Saroglitazar magnesium 2 mg and 4 mg treatment.

Trial Locations

Locations (9)

California Liver Research Institute; 🇺🇸 Pasadena, California, United States

Carolinas Healthcare System; 🇺🇸 Charlotte, North Carolina, United States

Schiff Center for Liver Diseases/University of Miami; 🇺🇸 Miami, Florida, United States

Gastrointestional Specialists of Georgia; 🇺🇸 Marietta, Georgia, United States

Indiana University School of Medicine; 🇺🇸 Indianapolis, Indiana, United States

Consultants for Clinical Research; 🇺🇸 Cincinnati, Ohio, United States

Rutgers NJ Medical School; 🇺🇸 Newark, New Jersey, United States

Hospital of the University of Pennsylvania; 🇺🇸 Philadelphia, Pennsylvania, United States

Einstein Medical Center Philadelphia; 🇺🇸 Philadelphia, Pennsylvania, United States